S100A9 and myocardial infarction: These findings advocate for a tailored therapeutic approach, suggesting short-term anti-S100A9 blockade during the early inflammatory phase post-MI, while long-term blockade could impair cardiac function recovery during the repair phase, underscoring the need for precise therapy duration determination (59).